NO20054133L - Antineoplastiske kombinasjoner omfattende at rapamycin derivat og en aromatase inhibitor - Google Patents

Antineoplastiske kombinasjoner omfattende at rapamycin derivat og en aromatase inhibitor

Info

Publication number
NO20054133L
NO20054133L NO20054133A NO20054133A NO20054133L NO 20054133 L NO20054133 L NO 20054133L NO 20054133 A NO20054133 A NO 20054133A NO 20054133 A NO20054133 A NO 20054133A NO 20054133 L NO20054133 L NO 20054133L
Authority
NO
Norway
Prior art keywords
aromatase inhibitor
rapamycin derivative
antineoplastic combinations
antineoplastic
combinations
Prior art date
Application number
NO20054133A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054133D0 (no
Inventor
Jr James Joseph Gibbons
Matthew L Sherman
Mark Berger
Robert T Maguire
Robert Friedman
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32962706&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20054133(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20054133D0 publication Critical patent/NO20054133D0/no
Publication of NO20054133L publication Critical patent/NO20054133L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20054133A 2003-03-05 2005-09-06 Antineoplastiske kombinasjoner omfattende at rapamycin derivat og en aromatase inhibitor NO20054133L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45228903P 2003-03-05 2003-03-05
PCT/US2004/006354 WO2004078133A2 (en) 2003-03-05 2004-03-01 Antineoplastic combinations comprising a rapamycin derivative and an aromatase inhibitor

Publications (2)

Publication Number Publication Date
NO20054133D0 NO20054133D0 (no) 2005-09-06
NO20054133L true NO20054133L (no) 2005-10-03

Family

ID=32962706

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054133A NO20054133L (no) 2003-03-05 2005-09-06 Antineoplastiske kombinasjoner omfattende at rapamycin derivat og en aromatase inhibitor

Country Status (20)

Country Link
US (1) US20040176339A1 (cg-RX-API-DMAC7.html)
EP (1) EP1603561A2 (cg-RX-API-DMAC7.html)
JP (1) JP2006519862A (cg-RX-API-DMAC7.html)
KR (1) KR20050109965A (cg-RX-API-DMAC7.html)
CN (1) CN1756549A (cg-RX-API-DMAC7.html)
AR (1) AR043403A1 (cg-RX-API-DMAC7.html)
AU (1) AU2004218439A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0408024A (cg-RX-API-DMAC7.html)
CA (1) CA2516353A1 (cg-RX-API-DMAC7.html)
CR (1) CR7942A (cg-RX-API-DMAC7.html)
EC (1) ECSP056001A (cg-RX-API-DMAC7.html)
MX (1) MXPA05009246A (cg-RX-API-DMAC7.html)
NI (1) NI200500148A (cg-RX-API-DMAC7.html)
NO (1) NO20054133L (cg-RX-API-DMAC7.html)
NZ (1) NZ542738A (cg-RX-API-DMAC7.html)
RU (1) RU2355399C2 (cg-RX-API-DMAC7.html)
TW (1) TW200529829A (cg-RX-API-DMAC7.html)
UA (1) UA83484C2 (cg-RX-API-DMAC7.html)
WO (1) WO2004078133A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200508029B (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
CN1829514A (zh) * 2003-07-25 2006-09-06 惠氏公司 Cci－779冻干制剂
RU2006122517A (ru) * 2004-01-08 2008-02-20 Вайет (Us) Фармацевтический состав для прямого прессования, предназначенный для перорального введения cci-779
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
MX2007005153A (es) * 2004-10-28 2007-06-26 Wyeth Corp Uso de un inhibidor del mtor en el tratamiento de leiomioma del utero.
DE602006021142D1 (de) 2005-02-03 2011-05-19 Gen Hospital Corp Verfahren zur behandlung von gefitinib-resistentem krebs
PE20070763A1 (es) * 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
CA2629245C (en) * 2005-11-21 2016-07-12 Novartis Ag Neuroendocrine tumor treatment
DE102006008074B4 (de) * 2006-02-22 2013-08-14 RUHR-UNIVERSITäT BOCHUM Behandlung von Krebs mit Geruchsrezeptor-Liganden
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
US20100081681A1 (en) * 2006-08-16 2010-04-01 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2692769T3 (es) 2008-06-17 2018-12-05 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
CN109464445A (zh) 2008-08-04 2019-03-15 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US20110212977A1 (en) * 2008-11-11 2011-09-01 Eli Lilly And Company P70 s6 kinase inhibitor and mtor inhibitor combination therapy
LT3000467T (lt) 2009-04-06 2023-04-11 Wyeth Llc Krūties vėžio gydymo schema naudojant neratinibą
WO2010118419A2 (en) * 2009-04-10 2010-10-14 Haiyan Qi Novel anti-aging agents and methods to identify them
JP6091431B2 (ja) * 2011-01-31 2017-03-15 ルコラス−エム．ディー．リミテッド 医薬的使用
US9682066B2 (en) * 2012-12-04 2017-06-20 University Of Cincinnati Methods of treating primary brain tumors by administering letrozole
WO2015014284A1 (zh) * 2013-07-31 2015-02-05 北京盛诺基医药科技有限公司 一种乳腺癌的治疗方法
CN106061482A (zh) * 2013-10-08 2016-10-26 拉姆医疗公司 用于治疗淋巴管平滑肌瘤病的雷帕霉素
CN106659686A (zh) 2014-04-04 2017-05-10 拉姆医疗公司 用于治疗年龄相关病况的可吸入雷帕霉素制剂
KR20170095807A (ko) 2014-10-07 2017-08-23 램 테라퓨틱스, 인코포레이티드 폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6A (en) * 1836-08-10 Thomas Blanchard Machine for forming end pieces of plank blocks for ships
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
IL102414A (en) * 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
PT1318837E (pt) * 2000-08-11 2004-12-31 Wyeth Corp Metodo de tratamenton de carcinoma positivo a receptor de estrogenio
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
CZ309178B6 (cs) * 2001-02-19 2022-04-20 Novartis Pharma Ag 40-O-(2-hydroxyethyl)rapamycin pro použití při léčení
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
DE60228699D1 (de) * 2001-04-06 2008-10-16 Wyeth Corp Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
PL367267A1 (en) * 2001-06-01 2005-02-21 Wyeth Antineoplastic combinations
US20030008923A1 (en) * 2001-06-01 2003-01-09 Wyeth Antineoplastic combinations
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569

Also Published As

Publication number Publication date
WO2004078133A3 (en) 2004-11-11
UA83484C2 (uk) 2008-07-25
EP1603561A2 (en) 2005-12-14
AR043403A1 (es) 2005-07-27
NZ542738A (en) 2009-02-28
CA2516353A1 (en) 2004-09-16
NI200500148A (es) 2006-03-30
TW200529829A (en) 2005-09-16
ZA200508029B (en) 2007-04-25
US20040176339A1 (en) 2004-09-09
RU2005130767A (ru) 2006-02-10
JP2006519862A (ja) 2006-08-31
ECSP056001A (es) 2006-01-27
KR20050109965A (ko) 2005-11-22
AU2004218439A1 (en) 2004-09-16
MXPA05009246A (es) 2005-10-19
BRPI0408024A (pt) 2006-02-14
CR7942A (es) 2006-02-07
NO20054133D0 (no) 2005-09-06
RU2355399C2 (ru) 2009-05-20
WO2004078133A2 (en) 2004-09-16
WO2004078133A8 (en) 2005-09-01
CN1756549A (zh) 2006-04-05

Similar Documents

Publication Publication Date Title
NO20054133L (no) Antineoplastiske kombinasjoner omfattende at rapamycin derivat og en aromatase inhibitor
NO20054369D0 (no) Anvendelse av en IBAT-inhibitor for behandling og profylakse av forstoppelse
DE60229922D1 (de) Kombinationen, ein antidiarrhoikum und epothilon oder ein epothilonderivat enthaltend
DE60228699D1 (de) Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil
DE602004031670D1 (de) Stabilisierende plasma- und generatorinteraktionen
IS2914B (is) Kínólín afleiður og notkun þeirra sem tálma sveppagerla
IS2529B (is) Nýjar spírótrísýklískar afleiður og notkun þeirra sem fosfódíesterasa-7-hindrar
IS7427A (is) 3-sýklýl-5-(5-hluta hringur sem inniheldur köfnunarefni) metýl-oxasólídínónafleiður og notkun þeirra sem bakteríueyðandi efna
ATE509917T1 (de) Gamma-secretase-inhibitoren
NO20064130L (no) Antineoplastiske kombinasjoner av CCI-779 og rituximab
EP1653970A4 (en) GSK-3 HEMMER AND ITS USES
CY1105892T1 (el) Θepαπεια του ξανθωματος με παραγωγα αζετιδινονης ως αναστολεις απορροφησης στepολης
NL1025873A1 (nl) Doseringsvormen en wijzen van behandeling met vegfr-remmers.
SG136149A1 (en) Plasma source coil and plasma chamber using the same
ATE382040T1 (de) Acylaminothiazolderivate und ihre vewrendung als beta-amyloid inhibitoren
SG153647A1 (en) Antineoplastic combinations
NO20054135D0 (no) Kipolinon/benzoksazin derivater og anvendelser derav
ECSP034866A (es) Combinaciones antineoplásticas
DE60302152D1 (de) Diaminothiazole und ihre anwendung als cdk4 inhibitoren
AR033012A1 (es) Combinaciones antineoplasicas
NO20053874L (no) Formulering og metoder for behandling av thrombocytemi
IS2490B (is) Bensóþíasól- og bensoxasól-4,7-díonafleiður og notkun þeirra sem cdc25 fosfatasatálma
DK1589976T3 (da) Anvendelse af en kombination af en aromatase-inhibitor, et progestin og et estrogen til behandling af endometriose
IS7970A (is) PDE4-hemlar til að meðhöndla eitlafrumuæxli
IS8390A (is) Notkun á gaboxadóli við meðhöndlun á svefnleysi

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application